a6-containing (a6*) nicotinic ACh receptors (nAChRs) are selectively expressed in dopamine (DA) neurons and participate in cholinergic transmission. We generated and studied mice with gain-of-function a6* nAChRs, which isolate and amplify cholinergic control of DA transmission. In contrast to gene knockouts or pharmacological blockers, which show necessity, we show that activating a6* nAChRs and DA neurons is sufficient to cause locomotor hyperactivity. a6
INTRODUCTION
Identification of the relevant nAChRs involved in (1) normal DA transmission, (2) disorders of the DA system, such as schizophrenia, Parkinson's disease, and ADHD, and (3) nicotine dependence is a major priority. a6* (* indicates that other subunits may be present in the pentameric receptor) nAChRs are highly and selectively expressed in DA neurons, with additional functional expression in locus coeruleus and retinal ganglion cells (Azam and McIntosh, 2006; Azam et al., 2002; Champtiaux et al., 2002; Gotti et al., 2005b; Le Novere et al., 1996) . a6* nAChRs are selectively inhibited by the marine cone snail peptide a-conotoxin MII (aCtxMII) (Cartier et al., 1996; Whiteaker et al., 2000) . Immunoprecipitation and aCtxMII-binding studies demonstrated that a6b2b3* and a6a4b2b3* pentamers are the predominant a6* nAChRs in striatum (Champtiaux et al., 2003; Zoli et al., 2002) . a6b2* receptors account for $30% of nicotine-stimulated DA release in striatum (Grady et al., 2002; Kaiser et al., 1998; Kulak et al., 1997) . b3 subunits are encoded by a gene adjacent to Chrna6, are usually coexpressed with a6, and are essential for a6* nAChR biogenesis and function (Cui et al., 2003; Gotti et al., 2005a) . a6* receptors exhibit the highest known sensitivity to nicotine and ACh in functional measurements on native receptors (Salminen et al., 2004) yet function poorly in heterologous expression systems (Drenan et al., 2008) . As a result, there has been little progress in defining selective agonists for a6* nAChRs or on other functional measurements. Furthermore, in midbrain DA neurons, studies of somatodendritic a6* receptors are complicated by the presence of a4b2* (non-a6), and selective antagonists of a4b2* (non-a6) have not been identified.
Many experiments with selective destruction of DA neurons show that the activity of such neurons is necessary for reinforcement of natural and artificial rewards. These cells exhibit tonic and phasic firing patterns (Grenhoff et al., 1986) , where phasic or ''burst'' firing carries salient information thought to predict imminent reward status (Schultz, 2002) . Pedunculopontine tegmentum (PPTg) and laterodorsal tegmentum (LDTg) fibers provide a cholinergic drive that strongly regulates DA neuron excitability and the transition to burst firing (Lanca et al., 2000) . Midbrain nAChRs in three locations respond to mesopontinederived ACh: (1) a7* nAChRs on glutamatergic terminals from cerebral cortex, (2) a4b2* nAChRs on GABAergic terminals and cell bodies, and (3) a4* and a6* somatodendritic nAChRs on DA neurons (Calabresi et al., 1989) . Nicotine interferes with normal cholinergic transmission to DA neurons, in part by modifying the weights of these various nAChR synapses. For example, nicotine at concentrations found in the CSF of smokers preferentially desensitizes a4b2* nAChRs regulating midbrain GABA release (Mansvelder et al., 2002) yet still permits a7* nAChR-regulated glutamate release (Mansvelder and McGehee, 2000) . This produces both disinhibition and direct excitation of DA neurons, increasing the probability of a switch to burst firing.
Nicotine also exaggerates the action of endogenous ACh in regulating DA release in striatum. Striatal cholinergic interneurons continually release ACh that activates nAChRs, which maintains background DA levels during tonic firing of midbrain DA neurons (Zhou et al., 2001) . However, DA release in response to burst firing of DA neurons is facilitated by a reduction in nAChR activity (Rice and Cragg, 2004; Zhang and Sulzer, 2004) . a6* receptors, due to their high sensitivity and their selective expression in DA cell bodies and presynaptic terminals, are probably key players in cholinergic control of DA release. We reasoned that genetic ''sensitization'' of these receptors would (1) amplify the role of a6* nAChRs in cholinergic control of DA transmission and (2) allow for selective pharmacological stimulation of these neurons. This approach would complement previous experiments using a6 knockout mice and a6* pharmacological blockade, demonstrating behavioral and physiological responses for which a6* nAChRs are sufficient.
We introduced a bacterial artificial chromosome (BAC) transgene into the mouse germline with a mutant copy of the mouse Chrna6 gene that rendered mutant a6* channels ''hypersensitive'' to endogenous ACh or exogenous nicotine. DA neuron excitability and DA release is greatly augmented in these mice, and they exhibit behavioral phenotypes consistent with increased DA neuron firing and/or DA release. These studies improve our knowledge of cholinergic regulation of the midbrain DA system and of a6* nAChR biology and have implications for the treatment of disorders involving changes in DA.
RESULTS

Production and Characterization of BAC a6
L9 0 S
Transgenic Mice
We selected a 156 kb mouse BAC clone containing the genomic Chrna6 (a6 nAChR) locus with substantial 5 0 and 3 0 flanking genomic regions for generating a targeting construct to faithfully recapitulate expression of Chrna6. a6 Leu280 (the Leu 9 0 residue in the M2 domain) was mutated to Ser via homologous recombination using a two-step selection/counterselection procedure in E. coli. (Figure S1A available online). The final construct was injected into fertilized mouse eggs, and six transgenic offspring were identified by genomic DNA sequencing and diagnostic PCR ( Figure S1B and S1C). To eliminate possible artifacts of transgene position/insertion, we analyzed two independently derived lines (lines 2 and 5), which have different transgene copy numbers ( Figure S1D ) and different genomic positions. Both mouse lines expressed mutant a6 L9 0 S mRNA in addition to wild-type (WT) a6 mRNA ( Figure S1E ). We found no difference in location or intensity of [
125 I]-a-conotoxin MII (aCtxMII) labeling in a6 L9 0 S versus WT brains, confirming correct regional expression of a6* nAChRs in mutant mice ( Figure S1F ). To corroborate this, we quantified a6*-binding sites. Membranes were prepared from striatum (ST), olfactory tubercle (OT), superior colliculus (SC) (regions that account for most a6*-binding sites), and thalamus (TH) (where most binding sites are a4b2*). [
125 I]-epibatidine binding, coupled with inhibition by unlabeled aCtxMII, revealed a6* and non-a6* (a4b2*) receptors ( Figure S1G ). Collectively, these results indicate that a6 L9 0 S mice exhibit normal levels and localization of neuronal nAChRs.
Spontaneous and Nicotine-Induced Hyperactivity in a6
L9 0 S Mice
We measured home cage horizontal locomotor activity for WT and a6 L9 0 S mice over a period of 48 hr. a6 L9 0 S mice were markedly hyperactive relative to WT control littermates ( Figure 1A ). This effect was restricted to lights off ( Figure 1B) , though there was a nonsignificant trend toward hyperactivity during lights on. Although WT mice show locomotor habituation when placed into a novel environment, a6 L9 0 S mice exhibit sustained activity.
We measured WT and a6 L9 0 S locomotor activity for 30 min after placement in a new home cage environment ( Figure 1C ). Activity during the first 15 min of the session was unchanged, but from t = 16 to 30 min, a6 L9 0 S mice exhibited significantly greater activity than WT littermates ( Figure 1D ). a6* nAChRs are highly expressed in DAergic neurons, and nicotine has psychomotor stimulant properties in rodents. We injected WT and a6 L9 0 S mice with nicotine and measured locomotor activity. Low doses of nicotine (0.15 mg/kg, i.p.) strongly activated locomotion in a6 L9 0 S mice but had no effect in WT mice ( Figure 1E ). To characterize the locomotor activation phenotype in a6 L9 0 S mice, we constructed a nicotine dose-response relation. WT mice exhibited locomotor suppression at doses of nicotine between 0.5 and 2.0 mg/kg, i.p. (Figure 1F ), consistent with previous work (Tapper et al., 2007) . In contrast, a6 L9 0 S mice exhibited steadily increasing locomotor responses between 0.02 and 0.15 mg/kg, i.p. nicotine, followed by a decline at 0.4 mg/kg, i.p and locomotor suppression similar to WT mice at 1.5 mg/kg, i.p. Thus, selective activation of a6* receptors results in locomotor activation rather than locomotor suppression. This phenotype was not a stress response, as saline injections did not produce locomotor activation ( Figure 1G ).
Locomotor activation in a6 L9 0 S mice was dependent on activation of nicotinic receptors; we noted a strong block of the locomotor response in a6 L9 0 S (but not WT) mice preinjected with mecamylamine (1 mg/kg, i.p.) ( Figure 1H ). Further, a6 L9 0 S locomotor activation acted through dopamine receptors; the response to 0.15 mg/kg, i.p. nicotine was completely inhibited by SCH23390 (D1DR antagonist; 2 mg/kg, i.p.) and partially inhibited by sulpiride (D2DR antagonist; 20 mg/kg, i.p.) ( Figure 1H ).
To determine whether a6 L9 0 S mice develop tolerance or sensitization to nicotine psychomotor stimulation, we injected groups of a6 L9 0 S mice once daily for 6 days with nicotine. Injection of 0.02 mg/kg, i.p. or 0.08 mg/kg, i.p. nicotine did not produce any change in locomotor behavior after repeated injections ( Figure 1I ). Nicotine also produces hypothermia in mice, and a4* hypersensitive mice exhibit this effect at nicotine doses $50-fold lower than WT mice (Tapper et al., 2004) . We found no difference between the hypothermia responses of WT and a6 L9 0 S mice (data not shown).
Augmented Nicotine-Stimulated DA Release from Presynaptic Terminals in a6 L9 0 S Mice Mouse a6* nAChRs expressed in midbrain DA neurons are located both on the cell body and on presynaptic terminals in caudate/putamen (CPu), nucleus accumbens (NAc), and striatal aspects of the olfactory tubercle (OT (I) Lack of sensitization or tolerance following repeated nicotine administration in a6 L9 0 S mice. Groups of a6 L9 0 S mice were injected with saline once daily for 3 consecutive days, followed by nicotine (0.02 mg/kg, i.p., or 0.08 mg/kg, i.p.) once daily for 6 consecutive days. Locomotor activity was measured as in (E), and nicotine-stimulated locomotor activity for each mouse was normalized to saline control injections (average of three saline injections) for the same mouse. Data are expressed as the percentage of the response to saline (set to 100%). All data are expressed as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
Neuron a6 * nAChRs and Cholinergic Control of DA Release a small but significant reduction in EC 50 for both transgenic lines relative to WT ( Figure 2G ). In OT, there was a slight increase in R max ( Figures 2D and S2 ) and a greater reduction in the EC 50 for a6 L9 0 S lines compared to WT ( Figure 2H ). We used aCtxMII to inhibit a6* receptors, revealing the contribution of a6* and non-a6* nAChRs to this augmented DA release. In ST and OT, we observed a significant increase in total DA release mediated by a6 at most nicotine concentrations ( Figures 2B and 2E ). Interestingly, this was accompanied by a concomitant decrease in the non-a6* (a4b2* mediated) component (Figures 2C and 2F) in a6 L9 0 S samples. In ST and OT, we measured a significant reduction in the EC 50 for the a6-dependent component and no were dissected and synaptosomes were prepared. DA release was stimulated with a range of nicotine concentrations (3 nM, 10 nM, 30 nM, 100 nM, 300 nM, 1 mM, 10 mM), and a concentration-response relation for each mouse line (n = 6 mice/line) is shown for total release (A). To determine the relative contribution of a6* and non-a6* receptors, striatal synaptosome samples were incubated with aCtxMII (50 nM). a6*-independent release is shown in (C), and aCtxMII-sensitive (a6* dependent) release is shown in (B).
(D-F) Hypersensitive DA release in olfactory tubercle of a6 L9 0 S transgenic mice is a6* dependent.
Olfactory tubercle (''OT'') was dissected from WT and a6 L9 0 S mice, and samples were processed as in (A) (I-K) a6* nAChRs do not participate in nicotinestimulated GABA release in striatum. ST and OT were dissected and combined, followed by synaptosome preparation. GABA release was stimulated by nicotine at the following concentrations: 100 nM, 300 nM, 1 mM, 3 mM, 10 mM, 30 mM, 100 mM, and 300 mM. Total (I) release and aCtxMIIsensitive (J) and resistant (K) components are shown. Data are expressed as mean ± SEM. *p < 0.05. change in EC 50 for the non-a6 component (Figures 2G and 2H) . Overall, DA release from a6 L9 0 S striatal synaptosomes may be underestimated by this assay, as 20 mM K + stimulated slightly less DA release in both a6 L9 0 S lines relative to WT mice ( Figure S2 ). These results directly reveal that selective a6* activation is capable of stimulating striatal DA release. a4b2* nAChRs modulate striatal GABA release (Lu et al., 1998) . We measured GABA release from striatal (ST and OT combined) synaptosomes of WT and a6 L9 0 S mice to determine whether any a6*-dependent component was revealed by the gain-of-function L9 0 S mutation. There was no difference in total GABA release for any genotype comparison (Figures 2I and S3) , and there was no a6* component (Figures 2J, 2K, and S3 Figure S3 ). This indicates that GABAergic terminals in striatum, either derived locally or from VTA or SNr GABAergic neurons, contain no appreciable a6* nAChRs. a6* receptors synthesized in retinal ganglion cells reside in the superficial layers of superior colliculus (SC) (Gotti et al., 2005b) , and we measured nicotine-stimulated 86 Rb + efflux from SC synaptosomes. a6 L9 0 S SC aCtxMII-sensitive receptors are hypersensitive to nicotine relative to WT, whereas aCtxMII-resistant 86 Rb + efflux is unchanged ( Figure S4 ).
DA Release and Locomotor Activity Are Precisely Controlled by Varying a6* Agonist Efficacy
The DA release data suggest a mechanism involving dopamine for the psychomotor stimulant action of nicotine as well as the spontaneous hyperactivity observed. For DA release in WT mice, TC 2429 ( Figure 3A ) (Bhatti et al., 2008 ) is a full agonist (versus nicotine) with 3-fold selectivity at a6b2* and a weak partial agonist at a4b2, whereas TC 2403 ( Figure 3E ) Lippiello et al., 1996 ) is a full agonist (versus nicotine) at Neuron a6 * nAChRs and Cholinergic Control of DA Release a4b2 and has no activity at a6b2* ( Figure S5 ). TC 2429, like nicotine, was more efficacious and more potent for DA release from striatal synaptosomes of a6 L9 0 S mice relative to WT ( Figure 3B ). In both a6 L9 0 S lines, R max was greater, and the EC 50 was reduced relative to WT. This was entirely attributable to a6* nAChRs ( Figure 3C ), which accounted for a greater proportion of the total response. There was a concomitant decline in the total response but not the EC 50 for a4b2* (aCtxMII resistant) nAChRs (Figure 3D) . We characterized the ability of TC 2429 to induce psychomotor activation in a6 L9 0 S and WT control mice. Similar to nicotine, injections of TC 2429 stimulated locomotor activity in a6 L9 0 S mice but not WT ( Figure 3I ). Unlike nicotine, TC 2429
did not produce locomotor suppression in WT mice. TC 2403 was slightly more potent and had equivalent efficacy for DA release in a6 L9 0 S versus WT striatum ( Figure 3F ). The increased potency was due to the amplification of an aCtxMIIsensitive response not visible in WT tissue preparations (Figure 3G) . TC 2403 was a partial agonist at this receptor ( Figure S5 ). Consistent with competition between a6 and a4 subunits for common b2 subunits, there was a decline in R max in a6
mice for a4b2* (aCtxMII resistant) nAChRs (Figures 3H and S5) . In locomotor assays, TC 2403 induced a slight locomotor activation in a6 L9 0 S but not WT mice ( Figure 3J ), consistent with partial activity at a6* nAChRs. Nicotine (10 mM) was used as a positive control for DA release for TC 2429 and TC 2403 ( Figure S5 ). For nicotine, TC 2429, and TC 2403, we noted a tight correlation between a6*-dependent DA release in vitro and peak locomotor activity in vivo ( Figure 3K ). These results suggest a mechanism whereby agonism at a6* nAChRs stimulates striatal DA release and produces locomotor stimulation, perhaps without GABAergic attenuation, which is normally coactivated by a4b2* activation ( Figures 2I-2K ). a6 L9 0 S Receptors Sensitize DA Neurons to Activation by Nicotine To directly determine whether DA neurons in a6 L9 0 S mice express hypersensitive a6* nAChRs, we prepared coronal midbrain slices ( Figure 4A ) and made patch-clamp recordings from VTA DA neurons in whole-cell configuration. DA neurons can be identified based on expression of tyrosine hydroxylase (TH) ( Figure 4B ) and with electrophysiology (Wooltorton et al., 2003) ; DA neurons exhibit pacemaker firing (1-5 Hz), membrane potential adaptations in response to hyperpolarizing current injections, and often express I h . We recorded currents induced by local nicotine application ( Figure 4C ) at a range of concentrations. Nicotinic currents in a6 L9 0 S neurons were markedly hypersensitive to nicotine; puffs of nicotine (1 mM) elicited inward currents that were larger than those seen in WT neurons at any concentration ( Figure 4D ). At all nicotine concentrations, a6 L9 0 S neurons of both transgenic lines showed larger average peak current responses than WT neurons ( Figure 4E ). Normalizing the peak current amplitude to cell capacitance yielded identical results ( Figure S6 ). Whole-cell responses to 1 mM nicotine were R90% blocked when aCtxMII (100 nM) was added to the perfusate ( Figure 4F , upper panel). aCtxMII block persisted 30 min after washout, consistent with previous work . Likewise, responses to 1 mM nicotine were 100% blocked in the presence of dihydro-b-erythroidine (DHbE, 2 mM), a potent inhibitor of most b2* receptors ( Figure 4F , lower panel). Although the general kinetics of these hypersensitive responses suggests that a6 L9 0 S receptors are postsynaptic, a presynaptic mechanism is not excluded by the data. To address this, we inhibited AMPA/kainate receptors with 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX, 15 mM) and voltage-gated Na + channels with tetrodotoxin (TTX, 0.5 mM). Inward current responses to 1 mM nicotine were unaffected by either CNQX or TTX ( Figure 4G ). Furthermore, we found no effect (n = 6, 0% block) on peak current amplitude (1 mM nicotine) in the presence of methyllycaconitine (MLA, 10 nM) ( Figure 4G ). Thus, hypersensitive a6* responses were consistent with a postsynaptic mechanism. VTA DA neuron pacemaker firing was unaltered in WT versus a6 L9 0 S slices ( Figure 4I ). To determine whether hypersensitive nicotinic receptors in a6 L9 0 S neurons were capable of acutely altering the excitability of VTA DA neurons, we recorded action potential firing in response to local nicotine application. Nicotine (1 mM) induced a transient increase in the instantaneous firing rate and a depolarization of the membrane potential ( Figure 4H ). There was a significant increase in the firing rate for a6 L9 0 S but not WT cells ( Figure 4I ). We noticed greater fluctuations in the holding current in a6
VTA DA neurons than in WT ( Figure 5A ). This suggests that some a6 L9 0 S channels are tonically active, reminiscent of previous observations in a4 nAChR L9 0 S and L9 0 A knockin mice (Labarca et al., 2001; Shao et al., 2008) . To determine whether this change in resting membrane conductance was due to active a6 L9 0 S channels, a6* receptors were blocked by application of aCtxMII. a6 blockade completely eliminated this increased channel noise in all a6 L9 0 S cells tested ( Figure 5B ). WT neurons bathed in aCtxMII served as a control ( Figure 5C ). To quantify this, we measured the root-mean-square (RMS) value of the fluctuations in WT and a6 L9 0 S voltage-clamp recordings. There was a significant decrease in the noise for a6 L9 0 S cells in the presence of aCtxMII ( Figure 5D ). We found no effect of CNQX, picrotoxin, or TTX on the increased membrane noise in a6 L9 0 S cells ( Figure S7 ).
DHbE, however, completely eliminated the increased noise similar to aCtxMII ( Figure S7) . These results further demonstrate that VTA DA neurons express functional, hypersensitive a6* nAChRs and that these receptors may be activated by local ACh. We examined the properties of hypersensitive a6* receptors in DA neurons of the substantia nigra pars compacta (SNc) and found similar results to the VTA. SNc DA neurons from a6 L9 0 S mice expressed hypersensitive nicotinic currents relative to WT, and firing rates were excited by 1 mM nicotine in a6 L9 0 S but not WT cells ( Figures S8A and S8B) . Finally, a6 L9 0 S SNc DA neurons expressed tonically active, aCtxMII-sensitive a6* receptors ( Figure S8C ).
Selective Expression of Functional a6* Receptors in Midbrain DA Neurons Although expression data suggest selective expression of a6* nAChRs in DA neurons, no electrophysiological experiments supporting this idea have been published. Midbrain DA neurons typically express D2-class autoreceptors, in contrast to midbrain GABAergic neurons . We recorded from 15 VTA neurons, ten of which expressed a6* nAChRs (based on large inward current responses to 1 mM nicotine) and five which . Nicotine (1 mM) was locally applied to VTA DA neurons in a6 L9 0 S slices before (black trace) and after (red trace) 10 min bath application of aCtxMII (100 nM) or DHbE (2 mM) (n = 5 for each antagonist). Scale bars: 100 pA, 3 s. (G) Hypersensitive nAChR activation is independent of AMPA receptor function, action potentials, and a7* nAChRs. The indicated drug was bath applied to VTA DA neurons in a6 L9 0 S slices, followed by activation of nAChRs with local application of 1 mM nicotine. Peak current amplitudes in the presence of 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), tetrodotoxin (TTX), or methyllycaconitine (MLA) were unchanged. Results from both mouse lines were identical in all cells tested (n = 3 for each drug). Scale bars: (Gi) 100 pA, 3 s; (Gii) 60 pA, 3 s; (Giii) 70 pA, 3 s. we observed hypersensitive nicotinic responses in a6 L9 0 S DA neurons, but not in GABA neurons ( Figure 6C ). Average peak current amplitudes were comparable between a6 L9 0 S lines 2 and 5 in SNc DA neurons ( Figure 6D , panel i). Average responses in WT and a6 L9 0 S GABA neurons were %10 pA ( Figure 6D , panel ii). Responses to nicotine at 1 mM were undetectable in WT DA and GABA neurons ( Figure 6C , panel i); however, these cells responded predictably to 100 mM or 1 mM nicotine (data not shown). As a control for the specificity of our results, we recorded from SNc and SNr neurons in slices from a4 L9 0 A mice. We found hypersensitive nicotinic responses in SNc and SNr neurons from these mice ( Figures 6C and 6D) , consistent with the idea that a4 is expressed in both DA and GABA cells . These results, coupled with the absence of a6* receptors in GABAergic presynaptic terminals in striatum ( Figures  2I-2K ), indicate that functional a6* receptors, in contrast to a4* receptors, are restricted to DA neurons in the midbrain.
The results thus far suggest increased DA tone in midbrain and/or striatum. To examine this, we studied pacemaker and nicotine-induced firing of VTA DA neurons in the absence and presence of sulpiride, a D2 DA receptor antagonist. There was no change in the ability of sulpiride to modestly increase baseline firing between WT and a6 L9 0 S VTA DA cells ( Figure S9 ). Further, sulpiride did not affect 1 mM nicotine-induced increases in firing in a6 L9 0 S cells or its lack of effect in WT cells ( Figure S9 ). To determine whether augmented striatal DA release in a6 L9 0 S mice (Figure 2 ) could be detected in brain slices using patch-clamp recordings, we studied striatal cholinergic interneurons. These cells are readily identifiable ( Figure S10A ), their activity is modulated by DA, and they are the source of ACh that activates a6* receptors on presynaptic DA terminals. We detected no change in spontaneous firing between WT and a6 L9 0 S cells ( Figure S10B ).
The resting membrane potential for a6 L9 0 S line 2 (but not line 5)
was hyperpolarized compared to WT ( Figure S10C ). Although DA may modulate I h currents in cholinergic interneurons (Deng et al., 2007) , we found no difference between WT and a6 L9 0 S I h expression or function in these cells ( Figures S10D and S10E ).
nAChRs in Locus Coeruleus Neurons Do Not Account for Behavioral Phenotypes in Mutant Mice
To determine whether a6* activation in a6 L9 0 S mice might also stimulate locus coeruleus (LC) neuron firing, we recorded from LC neurons in coronal slices from WT and a6 L9 0 S mice ( Figure 7A ). LC neurons express tyrosine hydroxylase (TH) (Figure 7B ), exhibit spontaneous firing (1-2 Hz; Figure 7C , panel i), and lack I h ( Figure 7C , panels ii and iii). LC neurons from a6 L9 0 S mice exhibited larger responses to locally applied nicotine compared to WT cells and cells from a4 L9 0 A knockin mice ( Figures 7D and   7E ). Although these responses were sensitive to aCtxMII (Figure 7F ) and therefore a6 dependent, they were smaller and $10-fold less sensitive to nicotine than were receptors on VTA DA neurons (compare Figures 4E and 7E ). LC neurons were also able to fire action potentials in response to nicotine ( Figure 7G ), but at concentrations of nicotine 10-fold higher than for DA neurons ( Figure 7H ). The reduced sensitivity of LC a6* nAChRs relative to receptors on DA neurons suggests that they do not participate in the psychostimulant response to nicotine that we observed. In support of this, we found no change in the locomotor response to nicotine when prazosin (a1AR antagonist) or yohimbine (a2AR antagonist) were administered prior to challenge with nicotine ( Figure 1H ). ( Figure 1 ). Our electrophysiology and neurochemistry experiments reveal a major role for a6* nAChRs in regulating both DA neuron firing (Figures 4 and S8 ) and synaptic release of DA in the striatum (Figures 2 and 3 ). Our finding that a6* nAChRs are largely excluded from midbrain GABA neurons ( Figure 6 ) and from striatal GABAergic terminals ( Figures 2I-2K) , in stark contrast to a4b2* nAChRs, is sustained by our behavioral data suggesting relatively unrestrained DA transmission in a6 L9 0 S mutant mice. We propose a model in which specific functional expression of high-sensitivity a6 L9 0 S nAChRs in DA neurons renders these cells selectively hypersensitive ( Figure S11 ) to activation by endogenous ACh ( Figure 8B ) or by exogenous nicotine ( Figure 8D ). This likely reflects that, in WT mice or in humans, high-affinity a6* nAChRs are specifically poised to modulate the activity of monoamine neurotransmitters such as DA. These studies provide long-sought sufficiency data for a6* nAChRs, complementing studies utilizing a6* loss-of-function mutations and pharmacological blockade.
DISCUSSION
In Vivo a6* nAChR Stoichiometry and Biophysical Properties Revealed by a6 L9 0 S Mice
We observed similar levels of aCtxMII binding in a6 L9 0 S brains compared to WT controls ( Figures S1F and S1G ). This is interesting in light of the fact that the two a6 L9 0 S lines harbor multiple copies of the transgene ( Figure S1D ). Unlike an exon-replacement knockin approach, a6 L9 0 S BAC transgenic mice retain two copies of WT Chrna6. In DA neurons, a6 and a4 subunits compete for common, limiting nAChR subunits such as b2, possibly b3 and a5, and probably for unknown assembly factors or chaperone proteins that may be specific to this cell type. As a result, (B) Identification of substantia nigra (SN) DA and GABA neurons. A diagram of coronal sections (bregma À3.1 mm) from mouse brain containing SN pars compacta (SNc) and pars reticulata (SNr) is shown (Franklin and Paxinos, 2008) . SN DA versus GABA neurons were identified by (Bi) location: SNc contains DA neurons whereas SNr is largely GABAergic; (Bii) DA neurons express hyperpolarization-activated cation current (I h ); (Biii) DA neurons exhibit pacemaker firing (1-5 Hz), whereas GABA neurons fire at >10 Hz; (Biv) DA neurons have broad spikes (>2 ms), whereas GABA neurons have narrow (%1 ms) spikes. Scale bars: (Bii) 400 pA (current traces)/30 mV (voltage step), 0.5 s; (Biii) 50 mV, 1 s; (Biv) 50 mV, 1 ms. (C) Hypersensitive a6* nAChRs reveal selective expression in DA neurons. SN DA and GABA neurons were identified according to criteria in (B). Neurons in slices from WT, a6 L9 0 S , and a4 L9 0 A mice were patch clamped in whole-cell configuration, and nicotine (1 mM) was locally applied (arrow) to activate hypersensitive nAChRs. Representative recordings for each are shown. Scale bars: (WT and a6 L9 0 S ) 100 pA, 5 s; (a4 L9 0 A ) 200 pA (DA)/80 pA (GABA), 5 s.
(D) Quantification of current amplitudes from (C). Average peak current amplitude in response to 1 mM nicotine for each genotype and cell type is shown. Data are expressed as mean ± SEM.
Neuron a6 * nAChRs and Cholinergic Control of DA Release the level of functional a6* expression in a6 L9 0 S neurons is determined by a competition between WT and L9 0 S a6 subunits. Indeed, for every agonist tested, we observed diminished peak aCtxMII-resistant (a4b2* dependent) DA release in a6 L9 0 S ST/ OT (Figures 2 and 3 ) despite equal levels of a4b2*-binding sites ( Figure S1G ). Future crosses of a6 L9 0 S mice to a4, b2, and b3 nAChR heterozygous or homozygous KO mice will yield further insights into nAChR subunit stoichiometry in vivo.
We noted a large increase in the potency and efficacy of nicotine in whole-cell recordings from a6 L9 0 S DA neurons (Figures 4D and 4E). With respect to nicotinic channel engineering, the present studies are analogous to electrophysiological and Ca 2+ fluxbased measurements of hypersensitive nicotinic responses in a4 L9 0 S , a4 L9 0 A , and a7 L9 0 T knockin mice (Fonck et al., 2005; Labarca et al., 2001; Tapper et al., 2004; Wooltorton et al., 2003) . The augmented responses (increased efficacy) to agonist likely reflect an increased maximal probability of channel opening, P open , conferred by the L9 0 S mutation (Labarca et al., 1995) , while the increased potency results from this mutation shifting the agonist concentration-response relation to lower concentrations (Revah et al., 1991) . The increased noise in voltage-clamp recordings from a6 L9 0 S neurons probably arises from one of two effects: (1) the presence of ACh in the slice preparation that is secreted from terminals of severed mesopontine cholinergic axons or (2) unliganded openings. Future in vivo studies, such as recordings from awake, behaving animals, will help confirm whether a6 L9 0 S mouse spontaneous behavioral phenotypes are caused by the former or the latter.
Contrasting Cell-Specific Expression of a4* versus a6* nAChRs Leads to Behavioral Differences in a4 and a6 Gain-of-Function Mutant Mice a6 L9 0 S mice are viable and fertile, whereas full expression of a4 L9 0 S * receptors causes neonatal lethality due to excitotoxic death of DA neurons (Labarca et al., 2001 ). This could be due to differential expression of a4 and a6 in development; unlike a4 expression, peak a6 expression occurs well after birth (Azam et al., 2007) . It is also possible that a6 L9 0 S * receptors are comparatively insensitive to activation by choline at concentrations found in CSF.
In the mesostriatal and mesolimbic DA system, a4b2* nAChRs are expressed in DA neuron cell bodies, dendrites, and axon terminals, as well as in cell bodies and axon terminals of midbrain and striatal GABAergic neurons. Conclusive evidence for a6* nAChR expression, however, is restricted to DA neuron cell bodies and axon terminals. Our present results show that, in midbrain, manipulating a6* nAChR sensitivity affects only DA neurons ( Figures S11, 8B , and 8D), whereas sensitized a4* receptors simultaneously increase the sensitivity of DA neurons and their inhibitory GABAergic inputs (Figures 6, 8A, and 8C) . This circuit-level difference explains a distinction between the locomotor effects of nicotine in the two gain-of-function mouse strains. WT mice display a hypolocomotor response to nicotine, and a4 L9 0 A mice recapitulate the WT response, only at much lower doses (Tapper et al., 2007) . On the other hand, a6 L9 0 S mice exhibit a sign change: psychomotor stimulation by nicotine ( Figure 1F ). This cell-type difference in expression between a4 and a6 nAChR subunits may also lead to the behavioral differences between a4 L9 0 A and a6 L9 0 S mice in response to repeated nicotine injections. Repeated, selective activation of a4* nAChRs produces locomotor sensitization (Tapper et al., 2004 (Tapper et al., , 2007 , whereas repeated activation of a6* nAChRs produces neither tolerance nor sensitization ( Figure 1I ). Locomotor sensitization may require nicotinic activation of GABAergic transmission, which is afforded by a4* nAChRs but not a6* nAChRs . Alternatively, the mechanism of sensitization could involve nAChR upregulation, to which a4b2* receptors are particularly prone (Nguyen et al., 2003) but to which a6* receptors are apparently resistant (Perry et al., 2007) .
a6* nAChRs Preferentially Modulate the Mesolimbic versus Mesostriatal DA System
The VTA and NAc (mesolimbic DA pathway) are key mediators of the addictive properties of nicotine (Corrigall et al., 1994) , and a recent report using pharmacological blockade suggests that a6* nAChRs specifically mediate cholinergic modulation of DA release in NAc (Exley et al., 2007) . Our results support this in two ways: (1) we observe greater expression of a6* currents in VTA versus SNc neurons (compare Figures 4E, 6D , and S8A), and (2) DA release is more strongly controlled by a6* on VTAderived terminals versus SNc-derived terminals (compare EC 50 values in Figures 2G and 2H ). Although we cannot completely distinguish the contribution of dorsal versus ventral striatum in our behavioral experiments, our DA release data suggest that the first a6* nAChRs significantly activated by nicotine are those in the mesolimbic pathway. VTA b2* nAChRs are critical mediators of exploratory behavior in mice (Granon et al., 2003; Maskos et al., 2005) . The VTA is Figure 8A ). a6* nAChRs have the highest known sensitivity to ACh, making them excellent candidates to mediate the stimulatory action of endogenous ACh on DA neurons. The tonic activation of a6* nAChRs that we observe in midbrain slices is likely due to endogenous ACh. Although we observe no difference in DA neuron baseline firing in vitro ( Figures 4I and S8B ), tonic midbrain a6* nAChR activation may be sufficient in vivo to contribute to behavioral phenotypes in a6 L9 0 S mice. In striatum, tonic extracellular DA is controlled by presynaptic nAChRs via continuous, low-level ACh released from cholinergic interneurons (Zhou et al., 2001 ). This acts to maintain a high probability of DA release from the terminal during tonic firing (Rice and Cragg, 2004; Zhang and Sulzer, 2004) . Sensitization of a6* nAChRs (in a6 L9 0 S mice) likely modifies DA release at presynaptic terminals in addition to effects at DA neuron cell bodies; DA terminals with a6 L9 0 S channels presumably have a decreased failure rate for single spike-induced release. This is supported by in vitro electrochemical studies of a6*-dependent DA release (Exley et al., 2007) . Thus, genetic sensitization of DA neurons to ACh in midbrain and facilitation of DA release in striatum ( Figure 8B ) could easily account for the home cage hyperactivity and the sustained hyperactivity of a6 L9 0 S mutant mice when placed in a novel environment. These phenotypes are reminiscent of DA transporter knockdown mice, which also show hyperactivity and impaired response habituation (Zhuang et al., 2001) . Although a6*-regulated norepinephrine (NE) release does not contribute to nicotine psychomotor activation ( Figure 1H ), our results do not rule out a role for NE in a6 L9 0 S spontaneous hyperactivity. Future studies on the mechanisms of a6 L9 0 S mouse hyperactivity could be useful in understanding the causes of human hyperactivity, such as that observed in ADHD.
In a6 L9 0 S mice, low-dose nicotine stimulates psychomotor activation similar to amphetamine in WT animals ( Figure 1E ). Nicotine thus recapitulates the spontaneous hyperactivity we observe, though with different kinetics. The difference in response magnitude and duration between responses to novelty and responses to nicotine may reflect different agonist concentration and desensitization kinetics. After ACh is released from nerve terminals, it is hydrolyzed by acetylcholinesterase (AChE), which has a turnover rate of 10 4 /s (Wathey et al., 1979) and is abundant in DAergic areas. ACh may not reach concentrations, or remain long enough, to significantly desensitize a6* nAChRs, perhaps even those with mutant L9 0 S subunits. In contrast, nicotine is eliminated with a half-life of $7 min (Matta et al., 2007) -nearly 10 7 times longer-and can therefore desensitize receptors, especially b2* nAChRs (Mansvelder et al., 2002) . Bolus injections of nicotine in a6 L9 0 S mice potently activate mutant receptors, and the locomotor response decay kinetics could therefore be dominated by both receptor desensitization and metabolic breakdown of nicotine.
Therapeutic Targeting of DA Disorders with a6* nAChRs The cholinergic system is targeted by several drugs used to treat neural disorders such as Alzheimer's disease and Parkinson's disease (PD). There is a well-documented inverse correlation between smoking and PD (Ritz et al., 2007) , and other disorders that can be treated with DA drugs (ADHD, schizophrenia) are associated with a high incidence of smoking (de Leon et al., 1995; Pomerleau et al., 1995) . These findings suggest the important role played by the cholinergic system in DA transmission. Our results show that a sensitized response in DA neurons to endogenous ACh may cause a behaviorally relevant state of excess DA. Manipulations to decrease a6* nAChR function may, therefore, be a useful treatment for human disorders involving excess DA. This could be in the form of a competitive antagonist or via viral gene therapy designed to eliminate a6* activity. On the other hand, patients with PD (low DA) may be aided by a6* agonists or allosteric modulators to augment DA release from residual DA terminals (Quik and McIntosh, 2006) . Our data clearly show that an a6-selective compound potently stimulates both DA release and locomotor activity ( Figure 3) . Further, the absence of sensitization or tolerance to repeated a6* activation ( Figure 1I ) suggests that clinical a6* agonists may have reduced abuse liability. Unlike L -DOPA or direct DA receptor agonists/antagonists, compounds manipulating DA neuron firing by targeting a6* nAChRs might avoid well known use-dependent side effects such as dyskinesias.
EXPERIMENTAL PROCEDURES Bacterial Artificial Chromosome Recombineering and Transgenesis
For a complete description of the methods used for recombineering and transgenesis, see Supplemental Data. A bacterial artificial chromosome (BAC), RP24-149I12, containing the mouse a6 nicotinic receptor subunit gene (Chrna6) was obtained from the BACPAC Resource Center (BPRC) at Children's Hospital Oakland Research Institute (Oakland, CA). BAC recombineering was carried out using a Counter Selection BAC modification kit (Genebridges; Heidelberg, Germany). a6 nAChR Leucine 280 (Leu9 0 ) was mutated to a serine using a two-step selection/counterselection protocol. First, a 15 bp stretch of Chrna6 exon 5 containing the coding sequence for V278 through L282 was replaced with a cassette containing a tandem selection (neo)/counterselection (rpsL) marker. Neo was used to select positive recombinants, and an engineered NotI restriction site pair flanking the selection cassette was used to confirm the location of the exogenously inserted DNA within the BAC. In the second step, Chrna6 exon 5 was restored using counterselection. Bacterial cells were placed under selective pressure (via streptomycin sensitivity gained by insertion of the rpsL marker) to lose the neo-rpsL cassette and replace it with nonselectable DNA engineered to insert the Leu9 0 to Ser (L280S) mutation. The resultant strain harbored a BAC with no ectopic DNA in or around Chrna6. Injection-grade a6 L9 0 S BAC DNA was prepared via double CsCl banding (Lofstrand Labs; Gaithersberg, MD). To produce transgenic animals, BAC DNA was injected into the male pronucleus of recently fertilized FVB/N embryos and implanted into pseudopregnant Swiss-Webster surrogates. Transgenic founders were identified using tail biopsy DNA and PCR primers designed to detect the L9 0 S mutation. Founders were crossed to C57BL/6J (Jackson Labs; Bar Harbor, ME) to obtain germline transmission and to establish a colony, and transgenic mice were continually backcrossed to C57BL/6J.
Locomotor Activity
Locomotor activity was assayed similar to Fonck et al. (2005) and is described in Supplemental Data.
Neurotransmitter Release from Striatal Synaptosomes DA and GABA release from striatal synaptosomes was carried out similar to Grady et al. (2002) and Nashmi et al. (2007) and is described in Supplemental Data.
Patch-Clamp Electrophysiology
Methods for patch-clamp recordings are completely detailed in Supplemental Data. Transgenic and nontransgenic mice (midbrain, P17-P25; locus coeruleus, P21-P28; striatum, P42-P56) were anesthetized, followed by cardiac perfusion with oxygenated (95% O 2 /5% CO 2 ) ice-cold glycerol-based artificial CSF (gACSF). Coronal slices (midbrain, striatum: 250 mm; pons: 200 mm) were cut and allowed to recover for at least 1 hr at 32 C in regular, oxygenated artificial CSF (ACSF). Somatic recordings from visually identified midbrain, pontine, or striatal neurons were obtained using patch electrodes filled with internal pipette solution containing 135 mM potassium gluconate, 5 mM EGTA, 0.5 mM CaCl 2 , 2 mM MgCl 2 , 10 mM HEPES, 2 mM Mg-ATP, and 0.1 mM GTP.
Recordings were taken at 32 C with an Axopatch 1D amplifier, a 16 bit Digidata 1322A A/D converter, and pCLAMP9.2 software (all Molecular Devices Axon; Sunnyvale, CA). For nicotine application, a drug-filled micropipette was used to locally apply nicotine using pressure application. A piezoelectric translator rapidly moved the nicotine-filled pipette close to and away from the cell to avoid nAChR desensitization.
Immunohistochemistry and Spectral Confocal Imaging Coronal brain slices cut for patch-clamp recording were processed similar to Lerchner et al. (2007) and stained according to Drenan et al. (2005) . Spectral confocal imaging was similar to Drenan et al. (2008) . See Supplemental Data for more details.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures, Figures, and Tables and can be found with this article online at http://www. neuron.org/supplemental/S0896-6273(08)00756-3.
